Xerox survey: Millennials most cost-conscious about healthcare

According to a new survey financed by Xerox, Millennials, or individuals between the ages of 18 and 34, are the most cost-conscious generation when it comes to healthcare. Fifty percent have even delayed treatment due to the healthcare costs.

More than 750 U.S. adults who purchase health insurance for their household participated in the survey, which was conducted by BAV Consulting.

Gen Xers, or individuals ages 35 to 49, are the second most cost-conscious, according to the survey. Forty-five percent have delayed treatment due to cost in their lifetime.

“The move to consumerism in healthcare is upon us,” Connie Harvey, Xerox’s chief operating officer, Healthcare Business Group, said in a prepared statement. “This data gives a glimpse at how consumers weigh cost in the healthcare decision making process—insight critical to guiding payers and providers as they look to transition to value-based care models.”

The survey also found that having access to their own electronic health records is most important to Millennials, with Gen Xers not far behind. And respondents from all generations said they want their pharmacists, healthcare providers, and health insurance companies to “be more connected regarding their health.”

“In order for the value-based care paradigm to work, payers and providers need consumers, especially Millennials, to take control of their own care, but clearly they need help getting there,” Harvey said.

Xerox released this research at the 2016 HIMSS Annual Meeting & Exhibition in Las Vegas and can be found there at booth #8005.

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.